OSUR positive Adcom vote. SNSS interim data due 3Q. CYTR reverse split.

May 15, 2012 No Comments by

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) said today that it is on track to release interim data from its Phase 3 VALOR trial in acute myeloid leukemia, during 3Q 2012.

CytRx Corporation (Nasdaq: CYTR) today announced a reverse split of its common stock at a ratio of 1-for-7. CytRx’s common stock will begin trading on NASDAQ on a split-adjusted basis when the market opens onMay 16, 2012.

OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that the FDA Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation (17-0) for the its OraQuick In-Home HIV Test.

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “OSUR positive Adcom vote. SNSS interim data due 3Q. CYTR reverse split.”

Leave a Reply